Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Engels EA. Epidemiology of thymoma and associated malignancies. J. Thorac. Oncol. 5(10 Suppl. 4), S260–S265 (2010).
  MedlineGoogle Scholar
• 2 Detterbeck FC, Parsons AM. Thymic tumors. Ann. Thorac. Surg. 77, 1860–1869 (2004).
  MedlineGoogle Scholar
• 3 Kuo TT. Tumours of the thymus. In: World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Muller-Hermelink HK et al. (Eds). IARC Press, Lyon, France, 146–248 (2004).
  Google Scholar
• 4 Masaoka A, Monden Y, Nakahara K et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48, 2485–2492 (1981).
  Medline CASGoogle Scholar
• 5 Rajan A, Giaccone G. Treatment of advanced thymoma and thymic carcinoma. Curr. Treat. Options. Oncol. 9, 277–287 (2008).
  MedlineGoogle Scholar
• 6 Kelly RJ, Petrini I, Rajan A et al. Thymic malignancies: from clinical management to targeted therapies. J. Clin. Oncol. 29(36), 4820–4827 (2011).•• Excellent review on thymic tumors from the clinical perspective.
  Medline CASGoogle Scholar
• 7 Suzuki E, Sasaki H, Kawano O et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn. J. Clin. Oncol. 36, 351–356 (2006).
  MedlineGoogle Scholar
• 8 Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J. Cancer. Res. Clin. Oncol. 130, 222–224 (2004).
  Medline CASGoogle Scholar
• 9 Yoh K, Nishiwaki Y, Ishii G et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung. Cancer. 62(3), 316–320 (2008).
  MedlineGoogle Scholar
• 10 Yamaguchi H, Soda H, Kitazaki T et al. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung. Cancer. 52(2), 261–262 (2006).
  MedlineGoogle Scholar
• 11 Ionescu DN, Sasatomi E, Cieply K et al. Protein expression and gene amplifıcation of epidermal growth factor receptor in thymomas. Cancer 103(3), 630–636 (2005).
  Medline CASGoogle Scholar
• 12 Farina G, Garassino MC, Gambacorta M et al. Response of thymoma to cetuximab. Lancet. Oncol. 8, 449–450 (2007).
  MedlineGoogle Scholar
• 13 Palmieri G, Marino M, Salvatore M et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front. Biosci. 12, 757–761 (2007).
  Medline CASGoogle Scholar
• 14 Kurup A, Burns M, Dropcho S et al. Phase II study of gefıtinib treatment in advanced thymic malignancies. J. Clin. Oncol. 23(Suppl.), Abstract 7068 (2005).
  Google Scholar
• 15 Bedano PM, Perkins S, Burns M et al. A Phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J. Clin. Oncol. 26, S713(Suppl.), Abstract 19087 (2008).
  Google Scholar
• 16 Pan CC, Chen PC, Wang LS et al. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 43, 165–172 (2003).
  MedlineGoogle Scholar
• 17 Weissferdt A, Lin H, Woods D et al. HER family receptor and ligand status in thymic carcinoma. Lung Cancer 77, 515–521 (2012).
  MedlineGoogle Scholar
• 18 Girard N, Shen R, Guo T et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin. Cancer Res. 15(22), 6790–6799 (2009).
  Medline CASGoogle Scholar
• 19 Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J. Pathol. 202(3), 375–381 (2004).
  Medline CASGoogle Scholar
• 20 Srobel P, Hartmann M, Jakob A et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N. Engl. J. Med. 350(25), 2625–2626 (2004).
  MedlineGoogle Scholar
• 21 Bisagni G, Rossi G, Cavazza A et al. Long lasting response to the multikinase inhibitor bay 43–9006 (sorafenib) in a heavily pretreated metastatic thymic carcinoma. J. Thorac. Oncol. 4, 773–775 (2009).
  MedlineGoogle Scholar
• 22 Girard N. Thymic tumors: relevant molecular data in the clinic. J. Thorac. Oncol. 5(Suppl. 4), S291–S295 (2010).
  MedlineGoogle Scholar
• 23 Buti S, Donini M, Sergio P et al. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J. Clin. Oncol. 29, e803–e805 (2011).
  MedlineGoogle Scholar
• 24 Schirosi L, Nannini N, Nicoli D et al. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann. Oncol. 23, 2409–2414 (2012).
  Medline CASGoogle Scholar
• 25 Salter JT, Levis D, Yannoutsos C et al. Imatinib for the treatment of thymic carcinoma. Presented at: 44th American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
  Google Scholar
• 26 Giaccone G, Rajan A, Ruijter R et al. Imatinib mesylate in patients with WHO B3 thymoma and thymic carcinoma. J. Thorac. Oncol. 4(10), 1270–1273 (2009).
  MedlineGoogle Scholar
• 27 Palmieri G, Marino M, Buonerba C et al. Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother. Pharmacol. 69(2), 309–315 (2012).
  Medline CASGoogle Scholar
• 28 Cimpean AM, Raica M, Encica S et al. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann. Anat. 190, 238–245 (2008).
  MedlineGoogle Scholar
• 29 Tomita M, Matsuzaki Y, Edagawa M et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J. Thorac. Cardiovasc. Surg. 124, 493–498 (2002).
  MedlineGoogle Scholar
• 30 Sasaki H, Yukiue H, Kobayashi Y et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg. Today 31, 1038–1040 (2001).
  Medline CASGoogle Scholar
• 31 Isambert N, Freyer G, Zanetta S et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. Presented at: 44th American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
  Google Scholar
• 32 Li XF, Chen Q, Huang WX et al. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med. Oncol. 26, 157–160 (2009).
  MedlineGoogle Scholar
• 33 Dişel U, Oztuzcu S, Beşen AA et al. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 7, 109–112 (2011).
  Google Scholar
• 34 Neuhaus T, Luyken J. Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma. Target Onccol. 7, 247–251 (2012).
  MedlineGoogle Scholar
• 35 Fiedler W, Giaccone G, Lasch P et al. Phase I trial of SU14813 in patients with advanced solid malignancies. Ann. Oncol. 22(1), 195–201 (2011).
  Medline CASGoogle Scholar
• 36 Thomas A, Rajan A, Berman AW et al. Phase II trial of sunitinib in patients with thymic epithelial tumors (TET). Presented at: 50th American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2014.•• Phase II study demonstrated an unprecedented activity for a targeted agent in treatment of thymic carcinoma.
  Google Scholar
• 37 Girard N, Teruya-Feldstein J, Payabyab EC et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J. Thorac. Oncol. 5(9), 1439–1446 (2010).
  MedlineGoogle Scholar
• 38 Zucali PA, Petrini I, Lorenzi E et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 116(20), 4686–4695 (2010).
  MedlineGoogle Scholar
• 39 Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res. 13, 5834–5840 (2007).
  Medline CASGoogle Scholar
• 40 McKian KP, Haluska P. Cixutumumab. Expert Opin. Investig. Drugs 18, 1025–1033 (2009).
  Medline CASGoogle Scholar
• 41 Rajan A, Carter CA, Berman A et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, Phase 2 trial. Lancet Oncol. 15(2), 191–200 (2014).•• Cixutumumab demonstrated activity in relapsed thymomas with a disease-stabilizing effect.
  Medline CASGoogle Scholar
• 42 Steele NL, Plumb JA, Vidal L et al. A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14(3), 804–810 (2008).
  Medline CASGoogle Scholar
• 43 Giaccone G, Rajan A, Berman A et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J. Clin. Oncol. 29(15), 2052–2059 (2011).
  MedlineGoogle Scholar
• 44 Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 27(13), 2278–2287 (2009).
  Medline CASGoogle Scholar
• 45 Zucali PA, De Pas G, Palmieri G et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. Presented at: 50th American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 46 Besse B, Garassino MC, Rajan A et al. A Phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). Presented at: 50th American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 47 Simonelli M, Zucali PA, Lorenzi E et al. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. Eur. J. Cancer 49(5), 989–998 (2013).• Published report on the Phase I trial of sorafenib in combination with lapatinib.
  Medline CASGoogle Scholar